Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
暂无分享,去创建一个
R. Paschke | Karen So | L. Bastholt | A. Ho | J. Fagin | R. Tuttle | R. Elisei | L. Wirth | P. Rodien | M. Dedecjus | A. Gianoukakis | F. Vaisman | J. Tennvall | D. Viola | W. Inabnet | Danielle Carroll | T. Hovey | Bhavana Thakre
[1] P. Hou,et al. Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant , 2007, Clinical Cancer Research.
[2] S. Larson,et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. , 2011, The Journal of clinical investigation.
[3] V. Trovisco,et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.
[4] D. Gustafson,et al. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice , 2011, Cancer Chemotherapy and Pharmacology.
[5] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[6] R. Tuttle,et al. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.
[7] E. Palmer,et al. Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib , 2014, Clinical Cancer Research.
[8] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[9] M. Ranney,et al. Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.
[10] P. Ladenson,et al. BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.
[11] Kaliszewski,et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .
[12] R. Tuttle,et al. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.
[13] V. Seshan,et al. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. , 2018, The Journal of clinical endocrinology and metabolism.
[14] R. Tuttle,et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.
[15] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[16] R. Koche,et al. SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. , 2020, Cancer discovery.
[17] M. Amit,et al. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine , 2018, The Journal of clinical endocrinology and metabolism.
[18] V. Seshan,et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. , 2016, The Journal of clinical investigation.
[19] S. Filetti,et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.
[20] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[21] Lei Zhang,et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.
[22] G. Cevenini,et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.